Search
Empasiprubart
go.drugbank.com/drugs/DB16469InvestigationalEmpasiprubart is a humanized sweeping antibody designed to bind to C2, a protein in the complement cascade that leads to cell destruction when activated.[L50783]
Categories: Experimental Unapproved Treatments for COVID-19STC3141
go.drugbank.com/drugs/DB16475InvestigationalSTC3141, was investigated in clinical trial NCT04880694 to evaluate its safety and effect in subjects with severe COVID-19 pneumonia.
Categories: Experimental Unapproved Treatments for COVID-19STI-1499
go.drugbank.com/drugs/DB16487InvestigationalSTI-1499 (COVI-GUARD was under investigation in clinical trial NCT04454398 to evaluate its safety and efficacy in patients with moderate COVID-19.
Categories: Experimental Unapproved Treatments for COVID-19BCc1
go.drugbank.com/drugs/DB16504ExperimentalBCc1 is a nanomedicine that demonstrated potent anticancer effects in both in vitro and in vivo studies.
Categories: Experimental Unapproved Treatments for COVID-19Allovectin-7
go.drugbank.com/drugs/DB17439InvestigationalAllovectin-7 or allovectin-7(r) is a lipid complex that contains the DNA sequences encoding HLA-B7 and beta-2 microglobulin. … It was discontinued after it failed to improve the objective response rate or overall survival versus first-line chemotherapy in malignant melanoma.[A255207]
Cloxazolam
go.drugbank.com/drugs/DB01553ExperimentalCloxazolam is a benzodiazepine with anxiolytic, sedative/hypnotic, muscle relaxant, and antiepileptic effects. … The usual dose of cloxazolam in adults is 3-12mg/day for anti-anxiety.
Sulfametrole
go.drugbank.com/drugs/DB15975InvestigationalCategories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseTolciclate
go.drugbank.com/drugs/DB13360ExperimentalCategories: Antifungals for Topical Use, Antifungals for Dermatological UseBeclabuvir
go.drugbank.com/drugs/DB12225InvestigationalBeclabuvir has been used in trials studying the treatment of Hepatitis C, Chronic.
Categories: Antivirals for Systemic Use, Antiinfectives for Systemic UseVTP-201227
go.drugbank.com/drugs/DB05652ExperimentalVTP-201227 has a novel mechanism of action and is being developed as a topical agent for the treatment of psoriasis with potential extensions into other dermatological indications.